Natalia Castro
Executive Director, Cardiovascular & Metabolic Business Unit
Natalia Castro, Executive Director of Cardiovascular & Metabolic, is a seasoned leader at Worldwide Clinical Trials with over 20 years of experience in clinical trial planning, execution, and management, with a specialized focus on obesity and metabolic disorders. Her unwavering commitment to quality, compliance, and innovation positions her as a key driver in advancing research in these complex therapeutic areas. Natalia ensures that each clinical project not only meets but exceeds regulatory and scientific standards, empowering breakthroughs in understanding and treating obesity and metabolic conditions.
Ask Natalia a question
Submit an RFP. Ask a Question
Natalia actively collaborates with regulatory, medical, and biostatistics teams to align trial designs with stringent regulatory expectations, particularly in obesity and metabolic health. She skillfully identifies and resolves challenges during clinical trials, addressing critical issues such as patient safety concerns and protocol deviations—vital elements when navigating metabolic and obesity-related risk factors.
With a robust background in leading multi-site studies on obesity and metabolic diseases, Natalia has successfully reduced startup timelines by 50% while consistently meeting service targets for cost, quality, and efficiency. Her innovative approach in clinical trial management sets new benchmarks for excellence, particularly in obesity and metabolic disorder trials. She employs strategic thinking to enhance site selection, ensuring the inclusion of diverse patient populations that enrich trial validity and relevance.
Natalia's capability for creative problem-solving not only drives positive outcomes across trials but also enhances patient reach and data quality. Her dedication to progressing clinical research in obesity and metabolism extends to mentoring the next generation of clinical leaders. Additionally, her strategic project delivery approach has significantly increased client satisfaction, achieving a 90% success rate in trial initiation within planned timelines for obesity-focused studies.
